The Office for Research collaborates with companies, organizations, foundations, and government agencies. We help nurture the research infrastructure by leveraging resources and fostering an atmosphere of collaboration and inclusivity as part of our mission to support the research, scholarship, and creative endeavors of ALL Rutgers faculty.
The results of Rutgers research impact our quality of life, promote prosperity, and enrich humanity in so many ways—from detecting nuclear threats and crime to creating the world’s biggest network of ocean data to exploring the central nervous system. Rutgers continuously ranks among America’s highest-ranked research universities as a member of the Association of American Universities, comprised of 62 distinguished institutions in the United States and Canada that continually advance society through education, research, and discovery.
Looking for an invention or technology to commercialize? Explore our portfolio of technologies available for licensing.
For any marketing or business development related questions/inquiries, reach out to Eusebio Pires, PhD, MBA at marketingbd@research.rutgers.edu.
As part of its commitment to enhancing and simplifying research processes and policies for faculty and staff, the Office for Research (OfR) announced a major update to its Institutional Review Board (IRB) submission process with the launch of eIRB+. The OfR’s eIRB+ implementation team developed the new system in collaboration with over 500 Rutgers faculty and staff.
A Rutgers researcher has teamed up with a local high school student to build a machine-learning approach for screening current and existing drugs to determine which could potentially become effective treatments for addiction-related disorders.
Rutgers faculty elected to the newest class of fellows of the American Association for the Advancement of Science (AAAS) have made a difference in the treatment of Parkinson’s disease, are advancing the understanding of how the brain processes rewards and motivates behavior and are tackling life-or-death questions regarding the success of cancer drugs.
